Practice Parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): [RETIRED]

Suchowersky, Oksana; Gronseth, Gary S.; Perlmutter, Joel S.; Reich, Stephen G.; Zesiewicz, Theresa; Weiner, William J.

doi:10.1212/01.wnl.0000206363.57955.1b

Cited by 226 publications

(133 citation statements)

References 51 publications

Supporting

Mentioning

123

Contrasting

Unclassified

Order By: Relevance

“…Nonetheless, the 2004 update of the Movement Disorder Society's task force assessing PD treatments and the American Academy of Neurology subcommittee addressing this matter concluded that available evidence of selegiline helping to prevent clinical progression of PD was insufficient. [4][5][6] The MAO-B inhibitory property of selegiline was the initial basis for its consideration in clinical trials of neuroprotection. Unrelated to this effect is evidence in several models of neuronal injury suggesting that the selegiline metabolite desmethylselegiline has additional pharmacological properties similar to those of neurotrophins.…”

Section: Selegiline (Deprenyl)mentioning

confidence: 99%

“…The discussion in this review focuses on completed clinical studies and their implications for understanding the cause or causes of PD. This topic has been the subject of several reviews in recent years, including evidence-based therapeutics assessments by a subcommittee of the American Academy of Neurology 4 and by a task force of the Movement Disorder Society. 5,6 Symptomatic treatment of PD has obvious endpoints, including those rated by evaluation of disabilities, changes in motor features, onset of dyskinesias or motor fluctuations, and quality of life assessments.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Protection Against Parkinson’s Disease Progression: Clinical Experience

LeWitt

Taylor

2008

Neurotherapeutics

View full text Add to dashboard Cite

Summary:Treatments with potential neuroprotective capability for Parkinson's disease (PD) have been investigated in randomized, controlled, clinical trials and other studies since the mid-1980s. Although promising leads have arisen, no therapy has been proven to halt or slow disease progression. Several large-scale studies have highlighted progress in methodology, as well as the frustrations of translating laboratory science to practical applications. This review summarizes findings from clinical trials with several classes of compounds, including monoamine oxidase-B inhibitors (selegiline, lazabemide, rasagiline), dopaminergic drugs (ropinirole, pramipexole, levodopa), antioxidant strategies (␣-tocopherol), mitochondrial energy enhancers (coenzyme Q 10 , creatine), antiapoptotic agents (TCH346, minocycline, CEP-1347), and antiglutamatergic compounds (riluzole). Beyond small-molecule pharmacology, gene therapy approaches, such as delivering neurotrophic substances (e.g., neurturin) by viral vector, are the next generation of treatment options.

show abstract

Section: Selegiline (Deprenyl)mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Protection Against Parkinson’s Disease Progression: Clinical Experience

LeWitt

Taylor

2008

Neurotherapeutics

View full text Add to dashboard Cite

show abstract

“…Increasing number of patients are seeking for alternative treatments such as herbal therapies. 8 Many researchers had discovered the broad therapeutic potential of a mushroom species Ganoderma lucidum (Family: Ganodermataceae). Among the bioactive elements in G. lucidum, polysaccharides, triterpenes, and peptidoglycans are three major physiologically active constituents in G. lucidum.…”

Section: Introductionmentioning

confidence: 99%

Effect of Ganoderma lucidum on MPTP induced behavioral alterations in Swiss albino mice

Palanimuthu

Parasuraman

Dhanaraj

et al. 2016

JYP

View full text Add to dashboard Cite

Objectives: To investigate the behavioral effect of Ganoderma lucidum polysaccharides (GLPS) and triterpenoid fractions (GLTT) in Parkinson's induced mice. Methods: Parkinson's disease (PD) was induced by intraperitoneal administration of of 3 mg/kg 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). G. lucidum was collected, authenticated and extracted with water and methanol to obtain GLPS and GLTT extracts respectively. A dose of 50 mg/kg of GLPS and GLTT were administered orally to PD mice for five consecutive days. Behavioral studies such as forced swim test, rota-rod test, grip strength test and locomotor activity were conducted in all the animals before and after toxicant, GLPS and GLTT treatment. Results: The mice injected with MPTP induced reasonable extent of Parkinsonism. In forced swim test, after treatment with GLPS and GLTT, the time for the mice to stop swimming decreased. In grip strength test, the motor coordination of PD induced mice seemed to be higher when compared to the normal mice, GLPS and GLTT treated groups. In rota-rod test, treatment with GLPS and GLTT showed mild decrease in the time for the mice to fall from a rotating rod. The results of the locomotor test showed that the mice had an increase in its locomotor activity after being induced with MPTP and decreased after being treated with GLPS and GLTT. Conclusion: This preliminary study results indicate that both GLPS and GLTT extract has therapeutic benefit on the PD mice.

show abstract

“…16 Circuit class therapy differs from the conventional one therapist to one patient model as there are usually more than two patients involved at any one time. 16 Circuit class therapy has been shown to be effective in improving the mobility of people early after stroke, 16 in chronic stroke patients 17 and in people with a history of falls 18 Circuit class therapy has the potential to be a more effective means of providing a greater amount of physical therapy for people both within the hospital setting and in the community outpatient setting.…”

mentioning

confidence: 99%

“…15 In an ambulatory rehabilitation setting, exercise interventions targeting balance are commonly offered by physiotherapists in a group environment. [16][17][18][19] However, a review of the literature finds that there is a recurrent issue with the definition of what constitutes physiotherapy, as there is no uniform treatment approach. 12,20,21 A wide variety of exercise interventions make it difficult to determine which component is providing benefit.…”

mentioning

confidence: 99%

Evaluation of a Circuit Training Program for People with Parkinson’s Disease: A Pilot Study

Lan¹,

Goodwin²,

Bew³

2018

HPMIJ

View full text Add to dashboard Cite

Objective: The 3 objectives of this study were to determine if a circuit group exercise program targeting balance was effective and feasible for patients with Parkinson's disease; to determine if any improvements were sustained at 6 months post-intervention and to evaluate patients' quality of life pre-and post-intervention.Design: A pre and post observational clinical study.Subjects: Participants were community-dwelling patients with PD referred outpatient rehabilitation at metropolitan hospital. Methods:The intervention involved a weekly 1-hour circuit training class conducted for 8 weeks. Clinical measures of balance, mobility and quality of life were taken on commencement of the program, on completion of the program and at six months post completion.Results: There were significant improvements in some aspects of balance following completion of the program however these were not sustained at 6-months postintervention. Self-rated health status was generally poor, but program satisfaction was high. Conclusion:For this group of patient circuit balance classes were feasible and safe. Further studies are required to better examine the effects of this treatment approach for people with Parkinson's disease. The 3 objectives were to determine if a groupbased exercise program targeting balance was effective in patients with Parkinson's disease (PD); determine the sustainability of any improvements at 6 months postintervention and evaluate quality of life (QoL) pre-and post-intervention. Participants are community-dwelling patients with PD and balance impairment attending circuit balance classes between 2007 and 2010 (N=19). The intervention involves a weekly 1-hour group-based circuit training exercise class over 8 weeks. The outcome measures were: Timed Up and Go, Functional Reach, Step Test, and EQ-5D Health Questionnaire etc. There was a significant improvement in performance on the Step Test after the intervention. This was not sustained at 6-months post-intervention. Selfrated health status was generally poor, but program satisfaction was high. Circuit balance classes result in a short-term improvement in balance in patients with PD, but do not appear to alter QoL. The exercise intervention may offer additional benefits.

show abstract

Practice Parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): [RETIRED]

Abstract: Abstract-Objective:To define key issues in the management of Parkinson disease (PD) relating to neuroprotective strategies and alternative treatments, and to make evidence-based treatment recommendations. Methods: Two clinical questions were identified.

Cited by 226 publications

References 51 publications

Protection Against Parkinson’s Disease Progression: Clinical Experience

Protection Against Parkinson’s Disease Progression: Clinical Experience

Effect of Ganoderma lucidum on MPTP induced behavioral alterations in Swiss albino mice

Evaluation of a Circuit Training Program for People with Parkinson’s Disease: A Pilot Study

Contact Info

Product

Resources

About